<DOC>
	<DOCNO>NCT02127684</DOCNO>
	<brief_summary>The investigator would like investigate efficacy frequent treatment Lucentis subject persistent diabetic macular edema despite standard dose regimen .</brief_summary>
	<brief_title>Frequent Dosing Regimen Lucentis Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing</brief_title>
	<detailed_description>This open-label , subject mask , phase II study intravitreally administer ranibizumab subject persistent diabetic macular edema . Persistent diabetic macular edema define subject still central subfield thickness SD-OCT great 320 micron receive least 3 previous dos AntiVEGF therapy past 5 month . Consented , enrol subject randomize two subgroup : ( 1 ) standard dose monthly 0.3mg ranibizumab ( 2 ) 0.3mg ranibizumab give 2 week apart 5 dos follow monthly dosing .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year Diagnosis Type 1 Type 2 diabetes BCVA score use ETDRS method &gt; 24 &lt; 78 study eye screen visit 3 intravitreal injection AntiVEGF 5 month prior screen Presence diabetic macular edema define SDOCT CST &gt; 320 micron spectral domain machine Subjects meet follow criterion exclude study : AntiVEGF treatment study eye within 3 week prior screen Intravitreal Ozurdex treatment study eye within 12 week prior screen Intravitreal steroid treatment study eye within 8 week prior screen PRP focal laser study eye within 4 month prior screen Active iris neovascularization study eye Any ocular condition study eye , opinion investigator , severe enough compromise study result . History cataract surgery study eye within 3 month prior screen visit Uncontrolled systemic disease Current enrollment investigational drug study participation study within 30 day prior screen visit Female patient pregnant , nurse plan pregnancy childbearing potential use reliable mean contraception . Any condition reason ( include inability read ETDRS chart language barrier ) preclude patient 's ability comply study requirement include completion study . Known allergy , hypersensitivity contraindication study medication , component , fluorescein povidone iodine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>diabetic macular edema</keyword>
</DOC>